Cargando…

MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response

BACKGROUND: The DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT) causes resistance of cancer cells to alkylating agents and, therefore, is a well-established predictive marker for high-grade gliomas that are routinely treated with alkylating drugs. Since MGMT is highly epigenetical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Switzeny, Olivier J., Christmann, Markus, Renovanz, Mirjam, Giese, Alf, Sommer, Clemens, Kaina, Bernd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858829/ https://www.ncbi.nlm.nih.gov/pubmed/27158275 http://dx.doi.org/10.1186/s13148-016-0204-7

Ejemplares similares

Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome
por: Reich, Thomas R., et al.
Publicado: (2017)

Investigation of MGMT and DAPK1 methylation patterns in diffuse large B-cell lymphoma using allelic MSP-pyrosequencing
por: Kristensen, Lasse Sommer, et al.
Publicado: (2013)

Methylation enrichment pyrosequencing: combining the specificity of MSP with validation by pyrosequencing
por: Shaw, Richard J., et al.
Publicado: (2006)

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR
por: Håvik, Annette Bentsen, et al.
Publicado: (2012)

A Comparison of MGMT Testing by MSP and qMSP in Paired Snap-Frozen and Formalin-Fixed Paraffin-Embedded Gliomas
por: Lazarević, Milica, et al.
Publicado: (2023)

Analysis of RET promoter CpG island methylation using methylation-specific PCR (MSP), pyrosequencing, and methylation-sensitive high-resolution melting (MS-HRM): impact on stage II colon cancer patient outcome
por: Draht, Muriel X. G., et al.
Publicado: (2016)

Extent and prognostic value of MGMT promotor methylation in glioma WHO grade II
por: Karschnia, Philipp, et al.
Publicado: (2020)

Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients
por: Quillien, Véronique, et al.
Publicado: (2014)

Prognostic Role of Methylation Status of the MGMT Promoter Determined Quantitatively by Pyrosequencing in Glioblastoma Patients
por: Kim, Dae Cheol, et al.
Publicado: (2016)

Comparison Study of MS-HRM and Pyrosequencing Techniques for Quantification of APC and CDKN2A Gene Methylation
por: Migheli, Francesca, et al.
Publicado: (2013)

Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients
por: Estival, Anna, et al.
Publicado: (2019)

B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells
por: Roos, Wynand P., et al.
Publicado: (2014)

The Significance of MGMT Promoter Methylation Status in Diffuse Glioma
por: Jovanović, Nikola, et al.
Publicado: (2022)

Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions
por: Bienkowski, Michal, et al.
Publicado: (2015)

Combining MGMT promoter pyrosequencing and protein expression to optimize prognosis stratification in glioblastoma
por: Li, Mingxiao, et al.
Publicado: (2021)

Do we really know who has an MGMT methylated glioma? Results of an international survey regarding use of MGMT analyses for glioma
por: Malmström, Annika, et al.
Publicado: (2020)

MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas
por: Hosoya, Tomohiro, et al.
Publicado: (2022)

CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells
por: Barrantes-Freer, Alonso, et al.
Publicado: (2015)

The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma
por: Villani, Veronica, et al.
Publicado: (2015)

Diagnostic Accuracy of Immunohistochemistry in Detecting MGMT Methylation Status in Patients with Glioma
por: Sahara, Nita, et al.
Publicado: (2021)

MGMT promoter methylation in 1p19q-intact gliomas
por: Kinslow, Connor, et al.
Publicado: (2023)

Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma
por: Zappe, Katja, et al.
Publicado: (2023)

Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53
por: Naumann, S C, et al.
Publicado: (2009)

The value of MGMT promote methylation and IDH-1 mutation on diagnosis of pseudoprogression in patients with high-grade glioma: A meta-analysis
por: Zhou, Min, et al.
Publicado: (2019)

Ten genes associated with MGMT promoter methylation predict the prognosis of patients with glioma
por: Zhang, Yang, et al.
Publicado: (2019)

Predicting MGMT Promoter Methylation in Diffuse Gliomas Using Deep Learning with Radiomics
por: Chen, Sixuan, et al.
Publicado: (2022)

O(6)-Methylguanine-DNA Methyltransferase (MGMT) mRNA Expression Predicts Outcome in Malignant Glioma Independent of MGMT Promoter Methylation
por: Kreth, Simone, et al.
Publicado: (2011)

DNA methylation analysis with methylation‐sensitive high‐resolution melting (MS‐HRM) reveals gene panel for glioma characteristics
por: Majchrzak‐Celińska, Aleksandra, et al.
Publicado: (2020)

The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients’ survival: a meta-analysis
por: Zhao, Hailong, et al.
Publicado: (2016)

Depatux-M and temozolomide in advanced high-grade glioma
por: Hirsch, Sophie, et al.
Publicado: (2020)

Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation
por: Christmann, Markus, et al.
Publicado: (2013)

Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma
por: Preusser, Matthias, et al.
Publicado: (2014)

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
por: van Nifterik, K A, et al.
Publicado: (2010)

Altered Expression of MGMT in High-Grade Gliomas Results from the Combined Effect of Epigenetic and Genetic Aberrations
por: Ramalho-Carvalho, João, et al.
Publicado: (2013)

Quality assessment of DNA derived from up to 30 years old formalin fixed paraffin embedded (FFPE) tissue for PCR-based methylation analysis using SMART-MSP and MS-HRM
por: Kristensen, Lasse S, et al.
Publicado: (2009)

High Specificity of Quantitative Methylation-Specific PCR Analysis for MGMT Promoter Hypermethylation Detection in Gliomas
por: Parrella, Paola, et al.
Publicado: (2009)

Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation
por: Fabi, Alessandra, et al.
Publicado: (2009)

MGMT Promoter Methylation and Parathyroid Carcinoma
por: Storvall, Sara, et al.
Publicado: (2019)

NI-02 THE ASSOCIATION BETWEEN (11)C-METHIONINE UPTAKE, IDH GENE MUTATION, AND MGMT PROMOTER METHYLATION IN PATIENTS WITH GRADE II AND III GLIOMAS
por: Okita, Yoshiko, et al.
Publicado: (2019)

Comprehensive Analysis of MGMT Promoter Methylation: Correlation with MGMT Expression and Clinical Response in GBM
por: Shah, Nameeta, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_mf86m8c4e573iakaq7eo5vldkq